Calendar

Important Dates 

Feb. 4th, 2013 ~ Support Group ~ Dr. Daniel Rayson

Mar. 4th, 2014 ~ Support Group ~ Health Basket ~ Health Foods that fight cancer.

April 1st, 2014~ Support Group 

May 6th, 2014 ~ Support Group

June 7th, 2014 ~ Support Group 

Sept. 2nd, 2014 ~ Support Group

Sept. 27th, 2014 ~ Pancreatic Cancer Awareness Walk/Run/Bike

Oct. 7th, 2014 ~ Support Group

Nov. 4th, 2014 ~ Support Group

November 2014 ~ Pancreatic Cancer Awareness

Dec. 2nd, 2014 ~ Support Group

» View Calendar

 

Recent Video

Support Group Guest Speakers:

Dr. Scott Hurton on Pancreatic Cancer care research in Nova Scotia:

Debbie Matheson on being a caregiver:

Dr. Mark Walsh on Pancreatic Cancer "How are we doing and where are we going?"

Celine Burlock on how to find peace:

Roy Ellis talks about grief and loss:

Rob Rutledge talks about the mind-body-spirit connection:

Timothy Walker talks about Mindfulness Based Stress Reduction:

Dr. Colin MacLeod talks about naturopathic medicine and cancer:

Dr. Daniel Rayson talks about pancreatic cancer:

Reverend David McGinley talks about spirituality and cancer:

Research Projects Funded by Craig's Cause Pancreatic Cancer Society

Research Project #1
Name: "Duodenopancreatectomy versus Best Supportive Care for Pancreatic Adenocarcinoma."
Researcher: Dr. Michele Molinari
Project Cost: $40,200.00

Many surgeons and physicians have been considering that the Whipple procedure is only a palliative therapy. In their opinion, the results are not good enough to suggest that the Whipple procedure should be offered to patients. Although they realize that without undergoing surgery, the mean survival is only 6 months, these doctors say that most of the patients with pancreatic cancer are quite advanced in their age and therefore they should not be operated on.

No previous research has focussed attention to the patients' perspective. As physicians, we recommend some treatments because they are the only available potential way to cure. Despite the fact that the Whipple fails for the majority of our patients, we are able to cure a few of them. Is that sufficient to support surgery for everyone? We don't know.

My interest is to find out. The Probability-Trade-Off (PTO) interview will provide us with an understanding as to what patients with pancreatic cancer, would decide if fully informed about their condition and the options available to them.

PTO is a formal, structured interview that makes patients go through a clinical situation. After being fully informed about the nature of the disease, the probabilities of success and failure, the patients are asked to choose between two or more treatments. Then, the probabilities of success and failures are changed in a progressive way so that one treatment becomes more appealing over the others. The difference between the starting probability and the probability when the patient changes her/his mind is called Minimal Probability Trade Off that the individual is willing to accept to undergo a therapy that is more invasive but that can potentially provide a better long term outcome.

This research technique is quite new and has not been used before for pancreatic cancer.

 Click on the following link to read the Protocal and to review the budget.

Download the Pdf

Research Project #2
Name: "CRTP General Public Summary"
Researcher: Dr. Scott Hurton
Budget: $36,000.00 (0ver 2 years)
Update: Dr. Scott Hurton was awarded the "The Colleen Elliott Award ." Established in 2011, the Colleen Elliott Award was created to honour excellence in cancer research training and is awarded to a research trainee who demonstrates the greatest promise and potential for excellence in cancer research.

Pancreatic cancer PC is a deadly malignancy, and although difficult to detect in early stages and treat, it can sometimes be cured through surgical resection. The pancreas lies behind the stomach, and is close to the liver, duodenum, and bile duct.  It produces and releases hormones such as insulin into the bloodstream and digestive enzymes into the small bowel.

Research has shown that some patients are not referred for surgery or chemotherapy, even though there is an increase in survival. It is unknown how many PC patients in Canada receive the most current treatment through their illness, and we are concerned that patients with PC do not receive the highest quality of care in Nova Scotia.

We will study a group of patients who developed PC in Nova Scotia over the past ten years, and this information will be used to examine the treatment of these patients. We will examine the quality of care we provide to them, by looking at the treatments they receive and see how many patients are receiving treatment according to the most recent evidence.  This will ensure that we are using the most up to date evidence on treatment after surgery for PC.   We plan to take this one step further and examine some of the reasons why patients do not receive the recommended treatment.   This will allow us to change the way we manage these patients, and potentially improve their quality of life during their treatment.

The information from this study will lead to future research that will further examine the healthcare resources used by PC patients.  This may allow us to use these resources for PC patients to improve their quality of life and potentially prolong their survival.

Research Project #3
Name: "CRTP General Public Summary"
Researcher: Dr. Moamen Bydoun
Budget: $36,000.00 (0ver 2 years)
Update: 

Pancreatic cancer is the fourth leading cause of cancer-related deaths in North America.

Less than 5% of patients survive more than five years after being diagnosed. The lethal nature of this cancer is mostly attributed to its ability to invade and occupy other vital organs of the body such as the liver, spleen, lungs and brain in a process called “metastasis”. Once metastasis is established, pancreatic cancer renders extremely difficult to treat with current therapies. More studies are then required to further understand the underlying biology of metastasis in pancreatic cancer in the hopes of developing new drugs targeting this process.

In our laboratory, we have established that a surface protein called p11 is an essential element in allowing cancer cells to become invasive, leave primary cancer sites, and reach the bloodstream eventually leading to metastasis. Depleting cancer cells from p11 causes a dramatic reduction in their invasive potential. Why p11 is important for cancer cells is simply because p11 regulates the production and activity of proteases. The latter are involved in breaking physiological barriers surrounding cancer cells allowing them to invade and “metastasize”.

To date, the role of p11 in pancreatic cancer is not established. It is known that human pancreatic cancers have elevated levels of p11 potentially providing a needed advantage for this cancer. Supported by our previous work on p11 and by promising preliminary results, we propose that p11 plays an important role in maintaining cancer growth and metastasis in pancreatic cancer. For this purpose, we will be utilizing cellular and molecular approaches to study how p11 regulates protease activity and contributes to the invasive potential of pancreatic cancer cells. We will also utilize a unique mouse model which closely mimics human pancreatic cancer to better define the contribution of p11. It will ultimately help us define if p11 is a “druggable” target for metastasis-preventing treatments.